BofA analyst Jason Gerberry lowered the firm’s price target on Immunovant (IMVT) to $38 from $45 and keeps a Buy rating on the shares. The firm ...

Guggenheim Securities adjusted its price target for Immunovant shares, listed on (NASDAQ:IMVT), to $44.00, a decrease from the previous $46.00, while sustaining a Buy rating on the stock. Currently ...

The Vivacity-MG3 study is currently in its open-label extension phase, which is investigating the longer-term safety and ...

Management projected strong growth for 2025, driven by expanded reimbursement in key European markets such as Spain and Italy and the expected completion of the post-approval efficacy study (PAES).

It’s show-me time for batoclimab, an antibody treatment from Immunovant and Roivant Sciences. Here's what you need to know.

Analyst Sam Slutsky of LifeSci Capital maintained a Buy rating on Immunovant (IMVT – Research Report), retaining the price target of ...

In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent ...

NEW YORK – Cartesian Therapeutics expects to launch a randomized, controlled Phase III trial, dubbed AURORA, to evaluate its investigational cell therapy for myasthenia gravis in the first half of the ...

Cemdisiran is under clinical development by Alnylam Pharmaceuticals and currently in Phase III for Myasthenia Gravis. According to GlobalData, Phase III drugs for Myasthenia Gravis have a 70% phase ...

The Ministry of Food and Drug Safety announced on the 20th that it has approved the severe myasthenia gravis treatment "Vyvgart" (active ingredient efgartigimod alpha) from Belgian pharmaceutical ...

There have been great advances in the field of generalised myasthenia gravis (gMG) in recent years, but many patients remain dissatisfied with their disease state despite being on treatment. There is ...